Andrew Hirsch 🇺🇸🟦

Opinions are my own

[Eyal Yakoby @EYakoby]

BREAKING: Live look at western university campuses after they learned that over 12,000 unarmed Iranian civilians have been massacred by the Islamic Republic.

[C4 Therapeutics @C4Therapeutics]

Happy #EmployeeAppreciationDay to our #C4TxTeam, a group of catalysts with a shared motivation to deliver transformative medicines to patients. To celebrate we all received a sweet treat – C4T M&Ms that hold a striking resemblance to our logo! Thank you for all that you do, team.

[C4 Therapeutics @C4Therapeutics]

Happy International Day of Women and Girls in Science! We welcomed women from @EwhaWomansUniv who are exploring #TPD's potential to impact patients. Our team had a fantastic day guiding them through our science and mission to create a new way to treat disease. #February11

[C4 Therapeutics @C4Therapeutics]

We announced anticipated milestones for 2025 as we advance our clinical portfolio of orally bioavailable #degrader medicines targeting cancers with high unmet needs. Read more in our latest press release: https://t.co/KSgRQOM8TZ #TPD

[C4 Therapeutics @C4Therapeutics]

We will present at the @jpmorgan 43rd Annual Healthcare Conference on Wednesday, January 15 at 2:15 p.m. PST in San Francisco. Learn more in our latest release: https://t.co/vB8p3Wn61K #TPD #biotech #JPM25

[Andrew Hirsch 🇺🇸🟦 @HirschAndrew]

Thank you to our partners and the entire #C4TxTeam for a year defined by continuous progress for our #TPD science, clinical programs and how we work as a team. Excited for the year ahead!

[C4 Therapeutics @C4Therapeutics]

2024 was a transformative year, one that elevated our discovery partnerships and clinical programs, welcomed new leaders and heightened our momentum to deliver transformative progress through #TPD science.

We're excited for all that's to come in 2025!

[Andrew Hirsch 🇺🇸🟦 @HirschAndrew]

I have deeply appreciated working with Stew, one of C4T’s first employees, since I joined the team four years ago. We will miss his enthusiasm for science and wish him the best in retirement!

[C4 Therapeutics @C4Therapeutics]

We celebrated Stew Fisher’s retirement and nearly ten years of dedication to C4T – including developing our TORPEDO® platform, establishing strong industry partnerships and delivering our first clinical development candidate.

Thank you, Stew, for your contributions to C4T!

[Andrew Hirsch 🇺🇸🟦 @HirschAndrew]

What a great team we have at C4T – a group that supports and motivates each other to one day make an impact on patients. Congratulations on this achievement!

[C4 Therapeutics @C4Therapeutics]

C4T has been recognized by the @BostonGlobe as a Top Place to Work in Massachusetts! Our team’s commitment to each other and shared passion for transforming lives through #TPD allows all of us to flourish, contribute and be our best. #topplacestowork #biotech

[Andrew Hirsch 🇺🇸🟦 @HirschAndrew]

Welcome, Steve!

[C4 Therapeutics @C4Therapeutics]

We are thrilled to welcome Steve Hoerter to our Board of Directors! Steve brings over three decades of executive management, commercial and board experience, including growing companies from clinical to commercial stage. Learn more: https://t.co/38f9r0S9ao

[C4 Therapeutics @C4Therapeutics]

At C4T, we take pride in sharing our love of science to the future catalysts of the world, including through our annual @ProjectOnramp internship program. On National #STEM Day, we encourage anyone interested in STEM to pursue this impactful career - one that can transform lives.

[Andrew Hirsch 🇺🇸🟦 @HirschAndrew]

Look forward to sharing an update on our cemsidomide program at #ASH24

[C4 Therapeutics @C4Therapeutics]

At the @ASH_hematology Annual Meeting in December we will present data from the ongoing Phase 1/2 trial of cemsidomide in multiple #myeloma and non-Hodgkin’s #lymphoma. Learn more in our latest release: https://t.co/VNWh92Tzkq #ASH24

[C4 Therapeutics @C4Therapeutics]

At the @ASH_hematology Annual Meeting in December we will present data from the ongoing Phase 1/2 trial of cemsidomide in multiple #myeloma and non-Hodgkin’s #lymphoma. Learn more in our latest release: https://t.co/VNWh92Tzkq #ASH24

[C4 Therapeutics @C4Therapeutics]

We announced third quarter 2024 financial results and recent business highlights. Read more here: https://t.co/2V4nI4cpCf

[C4 Therapeutics @C4Therapeutics]

C4T was recognized as a @BostInno Fire Awards honoree for our pharmaceutical partnerships, pipeline progress and appointment of new leaders who will help us develop a new generation of medicines. @BosBizJournal @bosbizevents #INNOFIRE

[C4 Therapeutics @C4Therapeutics]

Our leadership team will participate in multiple presentations and expert panel discussions at the #TPD and Induced Proximity Summit being held October 28-31 in Boston.

Learn more about C4T’s presence at the event in our latest release: https://t.co/FfIGr4tBhI

[C4 Therapeutics @C4Therapeutics]

At C4T we are committed to creating a new generation of medicines for people with #cancer – a disease that can change lives and leave a lasting impact.

Visit our website to explore our pipeline of #TPD therapies targeting cancer: https://t.co/f1g3KCnXER #WorldCancerResearchDay

[Andrew Hirsch 🇺🇸🟦 @HirschAndrew]

Thank you to everyone on our team and our investigators for pushing the field of #TPD forward. We can’t wait to keep up this momentum!

[C4 Therapeutics @C4Therapeutics]

#ESMO24 has wrapped and we're looking forward to continuing the momentum as we advance our medicines. We're encouraged by monotherapy data from the CFT1946 Phase 1 trial and the potential this brings to the field of #TPD.

Learn more about the trial: https://t.co/KPzMpBchXa

[Andrew Hirsch 🇺🇸🟦 @HirschAndrew]

So proud of this team. Looking forward to what’s ahead for C4T and our community of cancer researchers!

[C4 Therapeutics @C4Therapeutics]

Check out our team at #ESMO24!

We’ve had a blast being in Barcelona with a community committed to bringing new treatments to people impacted by #cancer. The passion we feel within every room at the event makes us even more excited to continue advancing our #TPD medicines.

[Andrew Hirsch 🇺🇸🟦 @HirschAndrew]

The strength of these preliminary results gives us a look into what the field of #TPD could become for patients – a new way to treat cancer. Excited for all that’s ahead at C4T!

[C4 Therapeutics @C4Therapeutics]

We presented preliminary Phase 1 data for CFT1946, the first clinical degrader targeting #BRAF V600 mutants. Data showed evidence of monotherapy anti-tumor activity and further validation of the potential of #TPD to change how disease is treated: https://t.co/r14Jkg36Fx #ESMO24

[Andrew Hirsch 🇺🇸🟦 @HirschAndrew]

Welcome to the team, Steve! We’re excited to have your guidance as we advance our medicines.

[C4 Therapeutics @C4Therapeutics]

We’re excited to announce the appointment of Stephen Fawell, a veteran biotech leader with decades of experience designing molecules that have advanced through late-stage development and regulatory approval, to our Board of Directors.

Read more: https://t.co/7Q34N7uVIe